• Kamal M Matar, Yousef Al-lanqawi, Kefaya Abdul-Malek, and Roger Jelliffe.
• Department of Pharmacology & Therapeutics, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Kuwait City 13110, Kuwait. kamal@hsc.edu.kw
• Biomed Res Int. 2013 Jan 1;2013:202818.

AbstractAmikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorithm. The estimations of the developed model were assessed using mean error (ME) as a measure of bias and mean squared error (MSE) as a measure of precision. A total of 331 serum amikacin concentrations were obtained from 56 patients. The mean (± SD) model parameter values found were Vc = 0.2302 ± 0.0866 L/kg, kslope = 0.004045 ± 0.00705 min per unit of creatinine clearance, k12 = 2.2121 ± 5.506 h(-1), and k21 = 1.431 ± 2.796 h(-1). The serum concentration data were estimated with little bias (ME = -0.88) and good precision (MSE = 13.08). The present study suggests that amikacin pharmacokinetics in adult Kuwaiti ICU patients are generally rather similar to those found in other patients. This population model would provide useful guidance in developing initial amikacin dosage regimens for such patients, especially using multiple model (MM) dosage design, followed by appropriate Bayesian adaptive control, to optimize amikacin dosage regimens for each individual patient.

19 keywords...

hide…